210 related articles for article (PubMed ID: 33798424)
1. Hematopoietic stem cell heterogeneity is linked to the initiation and therapeutic response of myeloproliferative neoplasms.
Tong J; Sun T; Ma S; Zhao Y; Ju M; Gao Y; Zhu P; Tan P; Fu R; Zhang A; Wang D; Wang D; Xiao Z; Zhou J; Yang R; Loughran SJ; Li J; Green AR; Bresnick EH; Wang D; Cheng T; Zhang L; Shi L
Cell Stem Cell; 2021 Apr; 28(4):780. PubMed ID: 33798424
[TBL] [Abstract][Full Text] [Related]
2. The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.
Spivak JL; Moliterno AR
Front Oncol; 2021; 11():641613. PubMed ID: 33777803
[TBL] [Abstract][Full Text] [Related]
3. The chronic myeloproliferative disorders: clonality and clinical heterogeneity.
Spivak JL
Semin Hematol; 2004 Apr; 41(2 Suppl 3):1-5. PubMed ID: 15190515
[TBL] [Abstract][Full Text] [Related]
4. [Allogeneic hematopoietic stem cell transplantation for myeloproliferative neoplasms].
Takenaka K
Rinsho Ketsueki; 2019; 60(9):1148-1156. PubMed ID: 31597838
[TBL] [Abstract][Full Text] [Related]
5.
Lin CHS; Zhang Y; Kaushansky K; Zhan H
Haematologica; 2018 Jul; 103(7):1160-1168. PubMed ID: 29567773
[TBL] [Abstract][Full Text] [Related]
6. The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche).
Zhan H; Kaushansky K
Adv Exp Med Biol; 2020; 1273():135-145. PubMed ID: 33119879
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic stem cells, progenitor cells and leukemic stem cells in adult myeloproliferative neoplasms.
Ng AP
Leuk Lymphoma; 2013 May; 54(5):922-33. PubMed ID: 23013358
[TBL] [Abstract][Full Text] [Related]
8. Favorable outcome of a patient with an unclassifiable myelodysplastic syndrome/myeloproliferative neoplasm treated with allogeneic hematopoietic stem cell transplantation.
Hemsing AL; Gjertsen BT; Spetalen S; Helgeland L; Reikvam H
SAGE Open Med Case Rep; 2021; 9():2050313X20988413. PubMed ID: 33628448
[TBL] [Abstract][Full Text] [Related]
9. Genetics of Myeloproliferative Neoplasms.
Szybinski J; Meyer SC
Hematol Oncol Clin North Am; 2021 Apr; 35(2):217-236. PubMed ID: 33641865
[TBL] [Abstract][Full Text] [Related]
10. Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.
Salit RB; Deeg HJ
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1023-35. PubMed ID: 25459177
[TBL] [Abstract][Full Text] [Related]
11. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation.
Kurosawa S; Shimomura Y; Tachibana T; Ishiyama K; Ota S; Kobayashi T; Uchida N; Fukushima K; Ashida T; Matsuoka KI; Kanda J; Ichinohe T; Atsuta Y; Murata M; Aoki J
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1607-1611. PubMed ID: 32454216
[TBL] [Abstract][Full Text] [Related]
12. Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms.
Prick J; de Haan G; Green AR; Kent DG
Exp Hematol; 2014 Oct; 42(10):841-51. PubMed ID: 25201757
[TBL] [Abstract][Full Text] [Related]
13. Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression.
Richter K; Pinto do O P; Hägglund AC; Wahlin A; Carlsson L
Haematologica; 2003 Dec; 88(12):1336-47. PubMed ID: 14687986
[TBL] [Abstract][Full Text] [Related]
14. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Yung Y; Lee E; Chu HT; Yip PK; Gill H
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440869
[TBL] [Abstract][Full Text] [Related]
15. Environmental Factors, Lifestyle Risk Factors, and Host Characteristics Associated With Philadelphia Negative Myeloproliferative Neoplasm: A Systematic Review.
Allahverdi N; Yassin M; Ibrahim M
Cancer Control; 2021; 28():10732748211046802. PubMed ID: 34645293
[TBL] [Abstract][Full Text] [Related]
16. Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms.
Monaco F; Scott BL; Chauncey TR; Petersen FB; Storer BE; Baron F; Flowers ME; Deeg HJ; Maloney DG; Storb R; Sandmaier BM
Haematologica; 2019 Jun; 104(6):1221-1229. PubMed ID: 30630975
[TBL] [Abstract][Full Text] [Related]
17. Inferring the initiation and development of myeloproliferative neoplasms.
Hermange G; Rakotonirainy A; Bentriou M; Tisserand A; El-Khoury M; Girodon F; Marzac C; Vainchenker W; Plo I; Cournède PH
Proc Natl Acad Sci U S A; 2022 Sep; 119(37):e2120374119. PubMed ID: 36083966
[TBL] [Abstract][Full Text] [Related]
18. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity.
James C; Mazurier F; Dupont S; Chaligne R; Lamrissi-Garcia I; Tulliez M; Lippert E; Mahon FX; Pasquet JM; Etienne G; Delhommeau F; Giraudier S; Vainchenker W; de Verneuil H
Blood; 2008 Sep; 112(6):2429-38. PubMed ID: 18612101
[TBL] [Abstract][Full Text] [Related]
19. Exploitation of the neural-hematopoietic stem cell niche axis to treat myeloproliferative neoplasms.
Herlihy N; Harrison CN; McLornan DP
Haematologica; 2019 Apr; 104(4):639-641. PubMed ID: 30930333
[No Abstract] [Full Text] [Related]
20. Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Takagi S; Masuoka K; Uchida N; Kurokawa M; Nakamae H; Imada K; Iwato K; Ichinohe T; Atsuta Y; Takami A; Yano S
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2208-2213. PubMed ID: 27667010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
